Oppenheimer lowered the firm’s price target on Viridian Therapeutics to $28 from $31 and keeps an Outperform rating on the shares. Top line data from VRDN-001’s pivotal THRIVE trial in active thyroid eye disease remain on track for September, and the firm’s recent scenario analysis supports favorable risk-reward. Although efficacy and safety demonstrated therein as well as in the THRIVE-2 trial in chronic TED will be closely scrutinized relative to Tepezza, Oppenheimer expects -001’s lower administration burden to serve as a competitive commercial advantage should clinical profiles lack differentiation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics reports Q2 EPS ($1.02) vs. ($1.27) last year
- VRDN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jefferies healthcare analyst holds an analyst/industry conference call
- Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks
- Viridian Therapeutics completes enrollment in THRIVE-2 trial